Navigation Links
TPI to Host First Quarter Fiscal Year 2014 Earnings Conference Call on Friday, November 15, 2013 at 8:30 a.m. ET
Date:11/11/2013

CHENGDU, China, Nov. 11, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the first quarter of fiscal year 2014 ended September 30, 2013 to be held at 8:30 a.m. ET on Friday, November 15th, 2013.

Interested parties may access the call by dialing

TOLL-FREE    1-877-941-1427
TOLL/INTERNATIONAL    1-480-629-9664 

It is advisable to dial in approximately 5 minutes prior to the start of the call.

Replay Dial-In Numbers:
TOLL-FREE   1-877-870-5176
TOLL/INTERNATIONAL   1-858-384-5517

From:  11/15/13 @ 11:30 am Eastern Time
To:    11/29/13 @ 11:59 pm Eastern Time
Replay Pin Number:  4649560

This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://public.viavid.com/index.php?id=106845

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list (EDL) of China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit:  http://www.tianyinpharma.com

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email: ir@tpi.asia

Tel:     +86-28-8551-6696 (Chengdu, China)
           +86-134-3655-0011 (China)

Address:

Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza     
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
4. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
5. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
6. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
7. Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement!
8. The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics
9. Eye Surgery Center of Michigan First in Southeast Michigan to Perform Bladeless Cataract Surgery Using New LenSx® Laser Technology
10. Amgen Announces 2012 First Quarter Dividend
11. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2017)... ... September 15, 2017 , ... San Diego based ... ‘Internal Seed B’ round of financing, totaling $600,000. The round was entirely ... ‘SAFE’ documentation structure at a company valuation of $10M. , Grolltex, ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... (CC) product portfolio, clinically-relevant starting and ancillary materials that generate unprecedented efficiencies ... Cell (hMSC)-based therapies. The CliniControl product portfolio will radically simplify major steps ...
(Date:9/14/2017)... ... September 14, 2017 , ... One of the world’s largest World ... , For six hours that day, the GenCure Marrow Donor Program will be signing ... H-E-B grocery stores in San Antonio. , The registration tables will be staffed by ...
(Date:9/13/2017)... ... September 13, 2017 , ... ... life sciences industry to improve patient outcomes and quality of life for more ... has been named a US expert to the International Standards Organization/Technical Committee ...
Breaking Biology Technology:
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
Breaking Biology News(10 mins):